← Leaderboards
Simon Daniel Spivack
Wadsworth Center
$10,594,156
Attributed
$16,510,949
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$16,018,690 · 13
CDC$492,259 · 1
By mechanism
U01$6,708,234 · 3
R01$4,582,106 · 2
R21$2,091,783 · 5
R33$1,048,432 · 1
RC1$998,815 · 1
K24$838,525 · 1
Top collaborators
- Jan No Middle Name Vijg20 shared
- Adam Auton5 shared
- Yousin Suh5 shared
- Olivier Loudig2 shared
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingLungMalignant Neoplasm Of LungBaseSmokerMalignant NeoplasmsEarly DiagnosisCellsTobacco SmokeTissuesCase ControlMolecularGene ExpressionGenesCancer RiskValidationBiological MarkersRisk AssessmentSmokingLinkLung DiseasesDna MethylationGenome-WideDesign
Grant awards (49)
Assessing genome sequence integrity in normal human cells$666,096
U01 · FY2022 · ES
Integrative, age-related changes in genome and epigenome in human lung in relation to smoking$663,615
U01 · FY2022 · HL · contact PI
Exhaled small RNA biomarkers to detect and monitor airway disease$515,716
R33 · FY2022 · HL · contact PI
Integrative, age-related changes in genome and epigenome in human lung in relation to smoking$664,116
U01 · FY2021 · HL · contact PI
Assessing genome sequence integrity in normal human cells$657,078
U01 · FY2021 · ES
Exhaled small RNA biomarkers to detect and monitor airway disease$532,716
R33 · FY2021 · HL · contact PI
Assessing genome sequence integrity in normal human cells$666,096
U01 · FY2020 · ES
Integrative, age-related changes in genome and epigenome in human lung in relation to smoking$652,342
U01 · FY2020 · HL · contact PI
Cross-Validation of Genome Integrity Assays in Primary Human Cells$167,834
U01 · FY2020 · ES
Cost-effective assessment of somatic mutational load$96,689
U01 · FY2020 · ES
Integrative, age-related changes in genome and epigenome in human lung in relation to smoking$661,440
U01 · FY2019 · HL · contact PI
Assessing genome sequence integrity in normal human cells$657,078
U01 · FY2019 · ES
Assessing genome sequence integrity in normal human cells$460,294
U01 · FY2018 · ES
Assessing genome sequence integrity in normal human cells$203,297
U01 · FY2018 · ES
Methylome characterization of bronchial epithelial projenitor cells$95,725
R21 · FY2018 · CA · contact PI
Methylome characterization of bronchial epithelial projenitor cells$84,405
R21 · FY2018 · CA · contact PI
Methylome characterization of bronchial epithelial projenitor cells$216,172
R21 · FY2017 · CA · contact PI
(PQB4) Age-cancer interplay of genome and epi-genome in human lung$700,211
R01 · FY2016 · CA
Exhaled microRNAs leveraged for lung cancer risk assessment$181,613
R21 · FY2016 · CA · contact PI
(PQB4) Age-cancer interplay of genome and epi-genome in human lung$571,652
R01 · FY2015 · CA
Clinical characteristics and outcomes of WTC-associated Sarcoidosis$492,259
U01 · FY2015 · OH · contact PI
(PQB4) Age-cancer interplay of genome and epi-genome in human lung$128,913
R01 · FY2015 · CA
Exhaled microRNAs leveraged for lung cancer risk assessment$110,342
R21 · FY2015 · CA · contact PI
Exhaled microRNAs leveraged for lung cancer risk assessment$107,593
R21 · FY2015 · CA · contact PI
Risk for Lung Cancer Asthma and COPD; Integrating Clinical and Airway Biomarker$46,641
K24 · FY2015 · CA · contact PI
(PQB4) Age-cancer interplay of genome and epi-genome in human lung$679,887
R01 · FY2014 · CA
Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker$121,064
K24 · FY2014 · CA · contact PI
(PQB4) Age-cancer interplay of genome and epi-genome in human lung$701,255
R01 · FY2013 · CA
Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker$167,705
K24 · FY2013 · CA · contact PI
Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker$167,705
K24 · FY2012 · CA · contact PI
Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker$167,705
K24 · FY2011 · CA · contact PI
Early Functional Genetic and Epigenetic Changes in Human Lung Carcinogenesis$499,186
RC1 · FY2010 · CA · contact PI
Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker$167,705
K24 · FY2010 · CA · contact PI
Early Functional Genetic and Epigenetic Changes in Human Lung Carcinogenesis$499,629
RC1 · FY2009 · CA · contact PI
Exhaled Breath DNA Methylation in Lung Carcinogenesis$186,817
R21 · FY2009 · CA · contact PI
Exhaled Breath DNA Methylation in Lung Carcinogenesis$235,126
R21 · FY2008 · CA · contact PI
Quantitative Gene Expression in Human Lung Epithelium$200,200
R01 · FY2007 · CA · contact PI
Quantitative Gene Expression in Human Lung Epithelium$166,884
R01 · FY2007 · CA · contact PI
Quantitative Gene Expression in Human Lung Epithelium$367,323
R01 · FY2006 · CA · contact PI
Individual Promoter SNP and CpG Methylation Signatures$149,038
R21 · FY2006 · CA · contact PI
Quantitative Gene Expression in Human Lung Epithelium$365,501
R01 · FY2005 · CA
Individual Promoter SNP and CpG Methylation Signatures$153,011
R21 · FY2005 · CA
Quantitative Gene Expression in Human Lung Epithelium$355,150
R01 · FY2004 · CA
Quantitative Gene Expression in Human Lung Epithelium$345,130
R01 · FY2003 · CA
Carcinogen Metabolism Enzyme Expression in Buccal Cells$193,715
R21 · FY2003 · CA
Carcinogen Metabolism Enzyme Expression in Buccal Cells$190,610
R21 · FY2002 · CA
Carcinogen Metabolism Enzyme Expression in Buccal Cells$187,616
R21 · FY2001 · CA
LUNG CANCER SUSCEPTIBILITY MARKERS IN SURROGATE TISSUES$121,527
K08 · FY2001 · ES
LUNG CANCER SUSCEPTIBILITY MARKERS IN SURROGATE TISSUES$121,527
K08 · FY2000 · ES